WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering key aspects of the company’s core technology for diabetes management. The allowed claims are directed to a system for glycemic control of a diabetic patient that includes a smartphone-based diabetes mobile application, which will provide patients with real-time insulin dosing guidance, leveraging Glytec’s proprietary insulin titration technology.
The goal of the system will be to optimize an individualized insulin dosing protocol in order to stabilize and maintain a patient’s blood glucose levels within a prescribed goal range by analyzing data received from the patient, such as blood glucose levels, diet, physical activity, treatment history, and other attributes. The system will also be able to provide individualized guidance on how to respond to unexpected glycemic excursions and alert a provider when additional intervention is appropriate.
“At Glytec, each and every employee is focused on a critical mission – to improve the lives of people with diabetes,” said Glytec’s Chief Medical Officer, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC. “Our solutions have successfully helped clinicians improve inpatient outcomes and reduce hospital readmissions via precise glucose management, and a mobile app that helps patients better control their glucose levels in their day-to-day lives will be a high-impact addition to our diabetes management platform.”
An integrated mobile app that assists the management of diabetes is especially relevant in today’s healthcare landscape given the rise of connected health. People with diabetes, and their families, are asking for solutions that leverage modern technologies to provide real-time access to data related to their health and well-being.
“This Notice of Allowance is representative of another exciting advancement in our efforts to improve diabetes care across the entire continuum, not just in the hospital,” said Bob Leonard, President & CEO of Glytec. “The shift to value-based payments and the development of innovative population health models along with the growth of EHRs and the emergence of smart, connected devices are collectively ushering in the era of data-driven care management. The opportunity and need to provide personalized therapy management solutions that can enhance medication effectiveness and adherence, improve wellness and reduce costs has never been greater.”
This application claims the benefit of an earlier patent application filed by Glytec, which claims additional subject matter related to the company’s core technology. Further patent applications covering other technologies of the company are currently pending before the U.S. Patent and Trademark Office as well.
Founded in 2006, Glytec is a rapidly growing digital heath company specializing in advanced technology for diabetes management. eGMS®, Glytec’s glycemic management information system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The cloud based, modular eGMS® centers on the Glucommander™ Suite of FDA-cleared, predictive dosing algorithms for IV, subcutaneous and pediatric dosing: Glucommander™ IV (FDA clearance 2006), Glucommander™ SubQ (FDA clearance 2010) and Glucommander™ Pediatrics (FDA clearance 2012). Comprehensive management of patients requiring insulin therapy is further enabled by seamless EHR integration (SmartClick®) and robust analytics (Glucometrics®) and surveillance (GlucoSurveillance®) capabilities. The unique breadth and depth of the eGMS® interventional clinical decision support tools allows providers to standardize processes and individualize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit http://www.glytecsystems.com/.